Chimeric receptors with 4-1BB signaling capacity provoke potent cytotoxicity against acute lymphoblastic leukemia

Gadner H, Haas OA, Masera G, Pui CH, Schrappe M . ‘Ponte di Legno’ Working Group – report on the Fifth International Childhood Acute Lymphoblastic Leukemia Workshop: Vienna, Austria, 29 April–1 May 2002. Leukemia 2003; 17: 798–803.

Verma A, Stock W . Management of adult acute lymphoblastic leukemia: moving toward a risk-adapted approach. Curr Opin Oncol 2001; 13: 14–20.

Pui CH, Campana D, Evans WE . Childhood acute lymphoblastic leukemia – current status and future perspectives. Lancet Oncol 2001; 2: 597–607.

Champlin R . T-cell depletion to prevent graft-versus-host disease after bone marrow transplantation. Hematol Oncol Clin North Am 1990; 4: 687–698.

Porter DL, Antin JH . The graft-versus-leukemia effects of allogeneic cell therapy. Annu Rev Med 1999; 50: 369–386.

Appelbaum FR . Haematopoietic cell transplantation as immunotherapy. Nature 2001; 411: 385–389.

Porter DL, Roth MS, McGarigle C, Ferrara JL, Antin JH . Induction of graft-versus-host disease as immunotherapy for relapsed chronic myeloid leukemia. N Engl J Med 1994; 330: 100–106.

Kolb HJ, Schattenberg A, Goldman JM, Hertenstein B, Jacobsen N, Arcese W et al. Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. European Group for Blood and Marrow Transplantation Working Party Chronic Leukemia. Blood 1995; 86: 2041–2050.

Slavin S, Naparstek E, Nagler A, Ackerstein A, Samuel S, Kapelushnik J et al. Allogeneic cell therapy with donor peripheral blood cells and recombinant human interleukin-2 to treat leukemia relapse after allogeneic bone marrow transplantation. Blood 1996; 87: 2195–2204.

Collins Jr RH, Shpilberg O, Drobyski WR, Porter DL, Giralt S, Champlin R et al. Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation. J Clin Oncol 1997; 15: 433–444.

Verdonck LF, Petersen EJ, Lokhorst HM, Nieuwenhuis HK, Dekker AW, Tilanus MG et al. Donor leukocyte infusions for recurrent hematologic malignancies after allogeneic bone marrow transplantation: impact of infused and residual donor T cells. Bone Marrow Transplant 1998; 22: 1057–1063.

Collins Jr RH, Goldstein S, Giralt S, Levine J, Porter D, Drobyski W et al. Donor leukocyte infusions in acute lymphocytic leukemia. Bone Marrow Transplant 2000; 26: 511–516.

Geiger TL, Jyothi MD . Development and application of receptor-modified T lymphocytes for adoptive immunotherapy. Transfus Med Rev 2001; 15: 21–34.

Schumacher TN . T-cell-receptor gene therapy. Nat Rev Immunol 2002; 2: 512–519.

Sadelain M, Riviere I, Brentjens R . Targeting tumours with genetically enhanced T lymphocytes. Nat Rev Cancer 2003; 3: 35–45.

Nadler LM, Anderson KC, Marti G, Bates M, Park E, Daley JF et al. B4, a human B lymphocyte-associated antigen expressed on normal, mitogen-activated, and malignant B lymphocytes. J Immunol 1983; 131: 244–250.

Campana D, Behm FG . Immunophenotyping of leukemia. J Immunol Methods 2000; 243: 59–75.

Cooper LJ, Topp MS, Serrano LM, Gonzalez S, Chang WC, Naranjo A et al. T-cell clones can be rendered specific for CD19: toward the selective augmentation of the graft-versus-B-lineage leukemia effect. Blood 2003; 101: 1637–1644.

Brentjens RJ, Latouche JB, Santos E, Marti F, Gong MC, Lyddane C et al. Eradication of systemic B-cell tumors by genetically targeted human T lymphocytes co-stimulated by CD80 and interleukin-15. Nat Med 2003; 9: 279–286.

Liebowitz DN, Lee KP, June CH . Costimulatory approaches to adoptive immunotherapy. Curr Opin Oncol 1998; 10: 533–541.

Allison JP, Lanier LL . Structure, function, and serology of the T-cell antigen receptor complex. Annu Rev Immunol 1987; 5: 503–540.

Salomon B, Bluestone JA . Complexities of CD28/B7: CTLA-4 costimulatory pathways in autoimmunity and transplantation. Annu Rev Immunol 2001; 19: 225–252.

Cardoso AA, Schultze JL, Boussiotis VA, Freeman GJ, Seamon MJ, Laszlo S et al. Pre-B acute lymphoblastic leukemia cells may induce T-cell anergy to alloantigen. Blood 1996; 88: 41–48.

Kim YJ, Kim SH, Mantel P, Kwon BS . Human 4-1BB regulates CD28 co-stimulation to promote Th1 cell responses. Eur J Immunol 1998; 28: 881–890.

Hurtado JC, Kim YJ, Kwon BS . Signals through 4-1BB are costimulatory to previously activated splenic T cells and inhibit activation-induced cell death. J Immunol 1997; 158: 2600–2609.

DeBenedette MA, Shahinian A, Mak TW, Watts TH . Costimulation of CD28− T lymphocytes by 4-1BB ligand. J Immunol 1997; 158: 551–559.

Bukczynski J, Wen T, Watts TH . Costimulation of human CD28− T cells by 4-1BB ligand. Eur J Immunol 2003; 33: 446–454.

Shuford WW, Klussman K, Tritchler DD, Loo DT, Chalupny J, Siadak AW et al. 4-1BB costimulatory signals preferentially induce CD8+ T cell proliferation and lead to the amplification in vivo of cytotoxic T cell responses. J Exp Med 1997; 186: 47–55.

Takahashi C, Mittler RS, Vella AT . Cutting edge: 4-1BB is a bona fide CD8 T cell survival signal. J Immunol 1999; 162: 5037–5040.

Martinet O, Divino CM, Zang Y, Gan Y, Mandeli J, Thung S et al. T cell activation with systemic agonistic antibody vs local 4-1BB ligand gene delivery combined with interleukin-12 eradicate liver metastases of breast cancer. Gene Ther 2002; 9: 786–792.

May Jr KF, Chen L, Zheng P, Liu Y . Anti-4-1BB monoclonal antibody enhances rejection of large tumor burden by promoting survival but not clonal expansion of tumor-specific CD8+ T cells. Cancer Res 2002; 62: 3459–3465.

Melero I, Shuford WW, Newby SA, Aruffo A, Ledbetter JA, Hellstrom KE et al. Monoclonal antibodies against the 4-1BB T-cell activation molecule eradicate established tumors. Nat Med 1997; 3: 682–685.

Melero I, Bach N, Hellstrom KE, Aruffo A, Mittler RS, Chen L . Amplification of tumor immunity by gene transfer of the co-stimulatory 4-1BB ligand: synergy with the CD28 co-stimulatory pathway. Eur J Immunol 1998; 28: 1116–1121.

Ye Z, Hellstrom I, Hayden-Ledbetter M, Dahlin A, Ledbetter JA, Hellstrom KE . Gene therapy for cancer using single-chain Fv fragments specific for 4-1BB. Nat Med 2002; 8: 343–348.

Mogi S, Sakurai J, Kohsaka T, Enomoto S, Yagita H, Okumura K et al. Tumour rejection by gene transfer of 4-1BB ligand into a CD80(+) murine squamous cell carcinoma and the requirements of co-stimulatory molecules on tumour and host cells. Immunology 2000; 101: 541–547.

Yoshida H, Katayose Y, Unno M, Suzuki M, Kodama H, Takemura S et al. A novel adenovirus expressing human 4-1BB ligand enhances antitumor immunity. Cancer Immunol Immunother 2003; 52: 97–106.

Manabe A, Coustan-Smith E, Kumagai M, Behm FG, Raimondi SC, Pui CH et al. Interleukin-4 induces programmed cell death (apoptosis) in cases of high-risk acute lymphoblastic leukemia. Blood 1994; 83: 1731–1737.

Stong RC, Korsmeyer SJ, Parkin JL, Arthur DC, Kersey JH . Human acute leukemia cell line with the t(4;11) chromosomal rearrangement exhibits B lineage and monocytic characteristics. Blood 1985; 65: 21–31.

Schneider U, Schwenk HU, Bornkamm G . Characterization of EBV-genome negative ‘null’ and ‘T’ cell lines derived from children with acute lymphoblastic leukemia and leukemic transformed non-Hodgkin lymphoma. Int J Cancer 1977; 19: 621–626.

Harmon JM, Norman MR, Fowlkes BJ, Thompson EB . Dexamethasone induces irreversible G1 arrest and death of a human lymphoid cell line. J Cell Physiol 1979; 98: 267–278.

Koeffler HP, Golde DW . Acute myelogenous leukemia: a human cell line responsive to colony-stimulating activity. Science 1978; 200: 1153–1154.

Sundstrom C, Nilsson K . Establishment and characterization of a human histiocytic lymphoma cell line (U-937). Int J Cancer 1976; 17: 565–577.

Nicholson IC, Lenton KA, Little DJ, Decorso T, Lee FT, Scott AM et al. Construction and characterisation of a functional CD19 specific single chain Fv fragment for immunotherapy of B lineage leukaemia and lymphoma. Mol Immunol 1997; 34: 1157–1165.

Warrens AN, Jones MD, Lechler RI . Splicing by overlap extension by PCR using asymmetric amplification: an improved technique for the generation of hybrid proteins of immunological interest. Gene 1997; 186: 29–35.

Nishigaki H, Ito C, Manabe A, Kumagai M, Coustan-Smith E, Yanishevski Y et al. Prevalence and growth characteristics of malignant stem cells in B-lineage acute lymphoblastic leukemia. Blood 1997; 89: 3735–3744.

Suzuki T, Coustan-Smith E, Mihara K, Campana D . Signals mediated by FcgammaRIIA suppress the growth of B-lineage acute lymphoblastic leukemia cells. Leukemia 2002; 16: 1276–1284.

Ito C, Tecchio C, Coustan-Smith E, Suzuki T, Behm FG, Raimondi SC et al. The antifungal antibiotic clotrimazole alters calcium homeostasis of leukemic lymphoblasts and induces apoptosis. Leukemia 2002; 16: 1344–1352.

Mihara K, Imai C, Coustan-Smith E, Dome JS, Dominici M, Vanin E et al. Development and functional characterization of human bone marrow mesenchymal cells immortalized by enforced expression of telomerase. Br J Haematol 2003; 120: 846–849.

Manabe A, Coustan-Smith E, Behm FG, Raimondi SC, Campana D . Bone marrow-derived stromal cells prevent apoptotic cell death in B-lineage acute lymphoblastic leukemia. Blood 1992; 79: 2370–2377.

Campana D, Manabe A, Evans WE . Stroma-supported immunocytometric assay (SIA): a novel method for testing the sensitivity of acute lymphoblastic leukemia cells to cytotoxic drugs. Leukemia 1993; 7: 482–488.

Ito C, Kumagai M, Manabe A, Coustan-Smith E, Raimondi SC, Behm FG et al. Hyperdiploid acute lymphoblastic leukemia with 51 to 65 chromosomes: a distinct biological entity with a marked propensity to undergo apoptosis. Blood 1999; 93: 315–320.

Srivannaboon K, Shanafelt AB, Todisco E, Forte CP, Behm FG, Raimondi SC et al. Interleukin-4 variant (BAY 36-1677) selectively induces apoptosis in acute lymphoblastic leukemia cells. Blood 2001; 97: 752–758.

Bartholomew A, Sturgeon C, Siatskas M, Ferrer K, McIntosh K, Patil S et al. Mesenchymal stem cells suppress lymphocyte proliferation in vitro and prolong skin graft survival in vivo. Exp Hematol 2002; 30: 42–48.

Krampera M, Glennie S, Dyson J, Scott D, Laylor R, Simpson E et al. Bone marrow mesenchymal stem cells inhibit the response of naive and memory antigen-specific T cells to their cognate peptide. Blood 2003; 101: 3722–3729.

Le Blanc K, Tammik L, Sundberg B, Haynesworth SE, Ringden O . Mesenchymal stem cells inhibit and stimulate mixed lymphocyte cultures and mitogenic responses independently of the major histocompatibility complex. Scand J Immunol 2003; 57: 11–20.

Li Y, Hellstrom KE, Newby SA, Chen L . Costimulation by CD48 and B7-1 induces immunity against poorly immunogenic tumors. J Exp Med 1996; 183: 639–644.

Walter EA, Greenberg PD, Gilbert MJ, Finch RJ, Watanabe KS, Thomas ED et al. Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor. N Engl J Med 1995; 333: 1038–1044.

Rooney CM, Smith CA, Ng CY, Loftin S, Li C, Krance RA et al. Use of gene-modified virus-specific T lymphocytes to control Epstein–Barr-virus-related lymphoproliferation. Lancet 1995; 345: 9–13.

MacCorkle RA, Freeman KW, Spencer DM . Synthetic activation of caspases: artificial death switches. Proc Natl Acad Sci USA 1998; 95: 3655–3660.

Marktel S, Magnani Z, Ciceri F, Cazzaniga S, Riddell SR, Traversari C et al. Immunologic potential of donor lymphocytes expressing a suicide gene for early immune reconstitution after hematopoietic T-cell-depleted stem cell transplantation. Blood 2003; 101: 1290–1298.

Introna M, Barbui AM, Bambacioni F, Casati C, Gaipa G, Borleri G et al. Genetic modification of human T cells with CD20: a strategy to purify and lyse transduced cells with anti-CD20 antibodies. Hum Gene Ther 2000; 11: 611–620.